Why Protagonist Therapeutics Shares Are Climbing
Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech.
Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech.
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be…
MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that are within anywhere from…
A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow they have for the rest of 2017.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly upward.
24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at ASCO.
Shares of Inovio Pharmaceuticals saw a massive gain early on Wednesday after the company announced a critical update from its HIV vaccine.
After Agilent Technologies reported its quarterly financial results late on Monday, investors were very happy with the beats on both the top and bottom lines. Analysts also took this opportunity to lift their price…
Testing for sexually transmitted diseases has become easier and more discrete as a new company has launched a home test kit.
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Endologix saw its shares hit a multiyear low following a meeting with the FDA concerning its Nellix Endovascular Aneurysm Sealing System.
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) has the potential to make or break companies, with winners walking away from this event with a nice gain and losers trying…
AbbVie watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office's Trial and Appeals Board that found in favor of Coherus Biosciences.
Syndax Pharmaceuticals has announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage of the Phase 2 trial and will reopen enrollment immediately.